To cite this article: Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care
impact on angioedema because of hereditary C1 inhibitor deficiency: a 21‐month …

Background Detailed demographic data on people with hereditary angioedema (HAE) and
acquired C1 inhibitor deficiency in the United Kingdom are relatively limited. Better …

To cite this article: Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A,
Zuraw B on behalf of HAWK (Hereditary Angioedema International Working Group) …

Background The treatment of hereditary angioedema (HAE) has undergone dramatic
changes as newer medicines have become available in recent years. Optimal care of these …

Objective To review the criteria for long-term prophylaxis therapy in patients with hereditary
angioedema due to C1 inhibitor deficiency (C1-INH-HAE), describe how these criteria have …

BACKGROUND: Hereditary angioedema (HAE) is a rare disease caused by C1 inhibitor
mutations. Although more than 100 mutations have been described, epidemiologic data are …

Introduction: Acquired angioedema with C1 inhibitor deficiency (AAE-C1-INH) is rare but a
potentially life-threatening disease. There are no official prevalence data, nor approved …

Background Acquired angioedema due to C1-inhibitor deficiency (C1-INH-AAE) is a rare
disease with no prevalence data or approved therapies. Objective To report data on patients …

Background Hereditary angioedema (HAE) is often caused by low serum levels or functional
deficiency in C1 inhibitor (C1-INH); however, in some cases, C1-INH serum level and …

Background Hereditary angioedema is a potentially life‐threatening disorder, because
edema occurring in the mucosa of the upper airways can lead to suffocation. The …